IL3 and small cell lung carcinoma: Human interleukin-3 (IL-3) assesses the tolerance, hematologic effects, and safety in individuals with small-cell lung cancer (SCLC) before and following multi-agent antineoplastic therapy in a randomized, placebo-controlled, double-blind study (49).